Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Bellerophon Therapeutics stock

BLPH
US0787713009
A2PZZR

Price

0.04
Today +/-
+0
Today %
+0 %
P

Bellerophon Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Bellerophon Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bellerophon Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bellerophon Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bellerophon Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bellerophon Therapeutics Stock Price History

DateBellerophon Therapeutics Price
9/27/20240.04 undefined
9/26/20240.04 undefined
9/25/20240.04 undefined
9/24/20240.04 undefined
9/23/20240.04 undefined
9/20/20240.04 undefined
9/19/20240.04 undefined
9/18/20240.04 undefined
9/17/20240.04 undefined
9/16/20240.04 undefined
9/13/20240.04 undefined
9/12/20240.04 undefined
9/11/20240.04 undefined
9/10/20240.04 undefined
9/9/20240.04 undefined
9/6/20240.04 undefined
9/5/20240.04 undefined
9/4/20240.04 undefined
9/3/20240.04 undefined

Bellerophon Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bellerophon Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bellerophon Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bellerophon Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bellerophon Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bellerophon Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bellerophon Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bellerophon Therapeutics’s growth potential.

Bellerophon Therapeutics Revenue, EBIT and net profit per share

DateBellerophon Therapeutics RevenueBellerophon Therapeutics EBITBellerophon Therapeutics Net Income
2028e284.42 M undefined0 undefined32.18 M undefined
2027e182.12 M undefined32.48 M undefined20.33 M undefined
2026e92.67 M undefined9.62 M undefined6.11 M undefined
2025e133.68 M undefined46.45 M undefined18.34 M undefined
2024e0 undefined-20.21 M undefined-22.7 M undefined
2023e5.75 M undefined-12.22 M undefined-12.47 M undefined
20220 undefined-22.38 M undefined-19.83 M undefined
20210 undefined-20.16 M undefined-17.76 M undefined
20200 undefined-26.28 M undefined-24.73 M undefined
20190 undefined-17.47 M undefined-13.27 M undefined
20180 undefined-27.88 M undefined2.81 M undefined
20170 undefined-24.6 M undefined-54.82 M undefined
20160 undefined-23.76 M undefined-23.81 M undefined
20150 undefined-48.24 M undefined-46.46 M undefined
20140 undefined-59.75 M undefined-59.67 M undefined
20130 undefined-62 M undefined-62 M undefined
20120 undefined-46.23 M undefined-46.23 M undefined

Bellerophon Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e
000000000005013392182284
---------------30.8397.8356.04
-----------------
00000000000000000
-46-62-59-48-23-24-27-17-26-20-22-12-20469320
------------240.00-34.599.7817.58-
-46-62-59-46-23-542-13-24-17-19-12-221862032
-34.78-4.84-22.03-50.00134.78-103.70-750.0084.62-29.1711.76-36.8483.33-181.82-66.67233.3360.00
0.790.790.790.8212.64.344.57.89.59.55000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Bellerophon Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bellerophon Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20122013201420152016201720182019202020212022
                     
0016.8224.0720.0231.8216.659.8747.5624.746.92
00000000000
00000000000
00000000000
0.321.5510.865.396.483.760.750.510.520.720.64
0.321.5527.6829.4626.535.5817.410.3848.0825.467.56
1.72.081.71.81.41.030.662.431.670.930.19
00000000000
00000000000
00000000000
00000000000
1.3304.017.161.80.20.30.30.490.490.19
3.032.085.718.963.21.230.962.732.161.420.37
3.353.6333.3938.4229.736.8118.3613.1150.2426.887.94
                     
0077.160.130.320.570.590.050.10.10.1
000130.9142.17176.15179.77193.31252.65253.77254.52
-114.52-176.52-54.22-100.68-124.49-179.31-176.5-189.76-214.49-232.25-252.08
103.4160.780-0.020000000
00000000000
-11.12-15.7422.9430.3318-2.593.863.638.2621.622.53
1.491.370.381.612.813.852.763.113.731.191.23
9.7212.629.426.313.53.234.784.486.713.864.17
00660150190000000
00000000000
000000000752203
11.2113.9910.468.076.57.087.547.5910.445.85.6
00000000000
00000000000
3.255.38005.2232.336.971.931.560.20
3.255.38005.2232.336.971.931.560.20
14.4619.3710.468.0711.7239.4114.519.52126.015.6
3.343.6333.438.429.7236.8218.3713.1250.2627.638.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Bellerophon Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bellerophon Therapeutics's financial health and stability.

Assets

Bellerophon Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bellerophon Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bellerophon Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bellerophon Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-46-62-59-46-23-542-13-24-17-19
00000000000
00000000000
52-13-125302-51
4111333-210200
00000000000
00000000000
-36-57-70-46-17-15-15-12-19-22-17
-30000000000
-300-1812230000
000-1712230000
00000000000
00000000000
0005425065700
395787541327065700
3957870112200000
00000000000
0016-10814-12-637-22-17
-39.7-57.96-70.56-46.72-17.23-15.9-15.5-12.94-19.88-22.82-17.77
00000000000

Bellerophon Therapeutics stock margins

The Bellerophon Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bellerophon Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bellerophon Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bellerophon Therapeutics's sales revenue. A higher gross margin percentage indicates that the Bellerophon Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bellerophon Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bellerophon Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bellerophon Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bellerophon Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bellerophon Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bellerophon Therapeutics Margin History

Bellerophon Therapeutics Gross marginBellerophon Therapeutics Profit marginBellerophon Therapeutics EBIT marginBellerophon Therapeutics Profit margin
2028e0 %0 %11.32 %
2027e0 %17.83 %11.16 %
2026e0 %10.38 %6.6 %
2025e0 %34.75 %13.72 %
2024e0 %0 %0 %
2023e0 %-212.35 %-216.84 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Bellerophon Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Bellerophon Therapeutics earnings per share therefore indicates how much revenue Bellerophon Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bellerophon Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bellerophon Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bellerophon Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bellerophon Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bellerophon Therapeutics Revenue, EBIT and net profit per share

DateBellerophon Therapeutics Sales per ShareBellerophon Therapeutics EBIT per shareBellerophon Therapeutics Earnings per Share
2028e23.26 undefined0 undefined2.63 undefined
2027e14.89 undefined0 undefined1.66 undefined
2026e7.58 undefined0 undefined0.5 undefined
2025e10.93 undefined0 undefined1.5 undefined
2024e0 undefined0 undefined-1.86 undefined
2023e0.47 undefined0 undefined-1.02 undefined
20220 undefined-2.34 undefined-2.08 undefined
20210 undefined-2.12 undefined-1.87 undefined
20200 undefined-3.37 undefined-3.17 undefined
20190 undefined-3.88 undefined-2.95 undefined
20180 undefined-6.42 undefined0.65 undefined
20170 undefined-9.46 undefined-21.08 undefined
20160 undefined-23.76 undefined-23.81 undefined
20150 undefined-58.83 undefined-56.66 undefined
20140 undefined-75.63 undefined-75.53 undefined
20130 undefined-78.48 undefined-78.48 undefined
20120 undefined-58.52 undefined-58.52 undefined

Bellerophon Therapeutics business model

Bellerophon Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of lung diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon's business model is based on the research and development of therapies for the treatment of severe respiratory diseases, particularly pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD). The company works closely with leading researchers and clinicians to develop innovative treatments that can improve the lives of patients with lung diseases. Bellerophon has several divisions aimed at expanding the portfolio of lung diseases. The first division is the development of INOpulse®, a therapy that improves lung function through inhaled nitric oxide (NO). This therapy specializes in the treatment of PH and has already been approved by the FDA in the United States, the European Commission, and other regulatory agencies worldwide. Another division of Bellerophon is the development of treatments using ultra-short-acting beta-agonists (uBAs), which are able to relax the respiratory muscles and improve breathing. This therapy specializes in the treatment of COPD and is based on a novel device designed to improve the effectiveness of uBA therapy. Bellerophon also has several programs in the pipeline for the development of therapies for the treatment of other lung diseases, including pulmonary fibrosis, lung cancer, and cystic fibrosis. These programs are still in the research phase but have the potential to bring forth new innovations in the future. Some of Bellerophon's products include INOpulse®, an inhaled nitric oxide treatment for PH, and the novel device that improves the effectiveness of uBA therapy for COPD. Additionally, the company is working on further product developments in the field of lung diseases. Overall, Bellerophon Therapeutics Inc has already made significant progress in the development of innovative therapies to improve lung function, particularly in the treatment of PH and COPD. With a strong pipeline of products and programs focused on exploring new therapies for the treatment of lung diseases, the company will continue to expand its position in the field of lung diseases and improve the lives of patients with severe respiratory diseases. Bellerophon Therapeutics is one of the most popular companies on Eulerpool.com.

Bellerophon Therapeutics SWOT Analysis

Strengths

Bellerophon Therapeutics Inc. has several strengths that contribute to its competitive advantage. Firstly, the company possesses a strong intellectual property portfolio, which grants exclusive rights to develop and commercialize its innovative therapeutic technologies. This provides a significant barrier to entry for potential competitors. Additionally, Bellerophon benefits from a talented and experienced team of researchers and scientists who are capable of driving the company's research and development efforts.

Weaknesses

While Bellerophon Therapeutics Inc. has several strengths, it also faces some weaknesses that may hinder its growth and success. One weakness is the company's heavy reliance on a limited number of key strategic partnerships for funding and resources. This dependence on external parties can present challenges in terms of maintaining control over the development and commercialization processes. Additionally, Bellerophon's limited product portfolio may restrict revenue generation potential. Diversification within the therapeutic market is crucial to mitigate this weakness.

Opportunities

Bellerophon Therapeutics Inc. operates within a rapidly evolving pharmaceutical industry, which presents various opportunities for growth and expansion. The increasing prevalence of chronic diseases and the aging population create a greater demand for innovative therapeutic solutions. Bellerophon can capitalize on this by continuing to advance its pipeline of promising drug candidates and technologies. Furthermore, the company could explore strategic collaborations with large pharmaceutical companies, enabling access to additional funding, expertise, and distribution channels.

Threats

Despite its potential, Bellerophon Therapeutics Inc. also faces threats that could impact its progress and competitiveness. One key threat is the highly regulated nature of the pharmaceutical industry. Compliance with stringent regulatory requirements may result in delays, increased costs, or even rejection of product candidates. Additionally, the entry of new competitors, especially those with greater financial resources and established market presence, could pose a significant threat to Bellerophon's market share. Lastly, an uncertain economic environment and changes in healthcare policies can also affect the company's potential for success.

Bellerophon Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bellerophon Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Bellerophon Therapeutics shares outstanding

The number of shares was Bellerophon Therapeutics in 2023 — This indicates how many shares 9.551 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Bellerophon Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bellerophon Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bellerophon Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bellerophon Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bellerophon Therapeutics stock splits

In Bellerophon Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Bellerophon Therapeutics.

Bellerophon Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.45 -0.16  (64.35 %)2023 Q3
6/30/2023-0.43 -0.42  (1.96 %)2023 Q2
3/31/2023-0.5 0.27  (153.48 %)2023 Q1
12/31/2022-0.49 -0.53  (-8.25 %)2022 Q4
9/30/2022-0.6 -0.53  (11.18 %)2022 Q3
6/30/2022-0.62 -0.43  (30.32 %)2022 Q2
3/31/2022-0.56 -0.59  (-6.13 %)2022 Q1
12/31/2021-0.61 -0.45  (26.47 %)2021 Q4
9/30/2021-0.64 -0.49  (23.75 %)2021 Q3
6/30/2021-0.67 -0.36  (46.25 %)2021 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Bellerophon Therapeutics stock

Eulerpool World ESG Rating (EESG©)

70/ 100

🌱 Environment

74

👫 Social

81

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bellerophon Therapeutics shareholders

%
Name
Stocks
Change
Date
8.39630 % Lepercq de Neuflize Asset Management, LLC1,026,8681,026,8681/26/2024
11.80095 % Aaron (Nelson Michael)1,443,256800,4122/22/2024
1.99712 % Amin (Naseem M.D.)244,248010/31/2023
1.63205 % Acadian Asset Management LLC199,600-183,57812/31/2023
0.49806 % Wang (Theodore T)60,913010/17/2023
0.35977 % Telemetry Investments, L.L.C.44,000-3,50012/31/2022
0.28331 % Fernandes (Peter)34,649010/31/2023
0.21237 % Dekker (Martin)25,973010/31/2023
0.20200 % Shah (Parag Suresh)24,705010/31/2023
0.08177 % Raymond James & Associates, Inc.10,000012/31/2023
1
2
3
4
5
...
6

Bellerophon Therapeutics Executives and Management Board

Ms. Mary Cloyd68
Bellerophon Therapeutics Independent Director
Compensation 97,402
Dr. Scott Bruder61
Bellerophon Therapeutics Independent Director
Compensation 84,902
Dr. Naseem Amin61
Bellerophon Therapeutics Independent Chairman of the Board
Compensation 83,100
Mr. Craig Jalbert61
Bellerophon Therapeutics President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Treasurer, Company Secretary, Director (since 2023)
Ms. Bobae Kim41
Bellerophon Therapeutics Vice President - Regulatory Affairs and Quality Assurance
1

Bellerophon Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Benchmark Electronics Stock
Benchmark Electronics
SupplierCustomer0,85-0,200,420,600,68-0,50
Flex Ltd Stock
Flex Ltd
SupplierCustomer0,590,670,500,600,57-0,72
Linde Stock
Linde
SupplierCustomer0,540,30-0,510,35-0,35-0,88
1

Most common questions regarding Bellerophon Therapeutics

What values and corporate philosophy does Bellerophon Therapeutics represent?

Bellerophon Therapeutics Inc is a pharmaceutical company focused on developing innovative therapies for respiratory diseases. The company is committed to improving the lives of patients by creating effective treatments that address unmet medical needs. With a strong emphasis on research and development, Bellerophon Therapeutics strives to advance scientific knowledge and provide groundbreaking solutions for respiratory conditions. By integrating cutting-edge technology and a patient-centric approach, the company aims to deliver transformative healthcare solutions. Bellerophon Therapeutics Inc prioritizes integrity, transparency, and collaboration in all aspects of its operations, working towards a common goal of improving respiratory health and enhancing patients' quality of life.

In which countries and regions is Bellerophon Therapeutics primarily present?

Bellerophon Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Bellerophon Therapeutics achieved?

Bellerophon Therapeutics Inc. has achieved several significant milestones. The company successfully completed its Phase 2b clinical trial for INOpulse® for Pulmonary Arterial Hypertension (PAH), demonstrating positive results in improving exercise capacity and quality of life for patients. Additionally, Bellerophon Therapeutics Inc. has received Fast Track designation from the U.S. FDA for INOpulse® for the treatment of PAH, highlighting its potential as a promising therapeutic option. Furthermore, the company has expanded its clinical development program to include additional indications, such as pulmonary hypertension associated with chronic obstructive pulmonary disease. Bellerophon Therapeutics Inc. aims to continue advancing its innovative therapies to address unmet medical needs in respiratory diseases.

What is the history and background of the company Bellerophon Therapeutics?

Bellerophon Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for cardiopulmonary diseases. Founded in 2009 and headquartered in New Jersey, the company has a strong history of advancing therapies to address unmet medical needs. Bellerophon's main focus lies in the development of INOpulse®, a pulsatile nitric oxide delivery system, which has shown promising potential in treating conditions like pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. With extensive research and development, Bellerophon Therapeutics Inc strives to improve the lives of patients with cardiopulmonary diseases through its innovative therapeutic solutions.

Who are the main competitors of Bellerophon Therapeutics in the market?

The main competitors of Bellerophon Therapeutics Inc in the market are XYZ Pharmaceutical Company, ABC Biotech Inc, and DEF Pharmaceuticals Corporation.

In which industries is Bellerophon Therapeutics primarily active?

Bellerophon Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Bellerophon Therapeutics?

Bellerophon Therapeutics Inc. operates under a business model focused on the development and commercialization of innovative therapies for cardiopulmonary diseases. The company leverages its expertise in biotherapeutics and medical devices to develop novel treatment options for conditions such as pulmonary hypertension, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). With a strong commitment to research and development, Bellerophon Therapeutics strives to address unmet medical needs and improve patients' lives by advancing its therapeutic candidates.

What is the P/E ratio of Bellerophon Therapeutics 2024?

The Bellerophon Therapeutics P/E ratio is -0.02.

What is the P/S ratio of Bellerophon Therapeutics 2024?

The Bellerophon Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Bellerophon Therapeutics?

The AlleAktien quality score for Bellerophon Therapeutics is 3/10.

What is the revenue of Bellerophon Therapeutics 2024?

The revenue cannot currently be calculated for Bellerophon Therapeutics.

How high is the profit of Bellerophon Therapeutics 2024?

The expected Bellerophon Therapeutics profit is -22.7 M USD.

What is the business model of Bellerophon Therapeutics

Bellerophon Therapeutics Inc is a company that focuses on the development of innovative medical therapies for severe respiratory diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey, USA. The main product of Bellerophon Therapeutics is INOpulse, a groundbreaking therapy for patients with pulmonary arterial hypertension (PAH) and certain types of pulmonary fibrosis. INOpulse utilizes nitric oxide (NO), a molecule naturally produced in the human lung that plays an important role in regulating blood flow and pressure. By administering INOpulse, the NO levels in the lungs are increased, resulting in improved blood and oxygen supply to the organs. Bellerophon Therapeutics also has a pipeline of products in development, including additional NO-based therapies for various respiratory diseases such as chronic obstructive pulmonary disease (COPD) and pneumonia. The company is also working on the development of drugs targeting other mechanisms of respiratory homeostasis, such as regulatory T cells. Bellerophon Therapeutics utilizes a combination of internal resources and external collaborations to advance its research and development activities. The company has its own state-of-the-art production facility for INOpulse and has formed partnerships with other companies and academic institutions to further develop and market its products. The business model of Bellerophon Therapeutics is based on the development and commercialization of innovative respiratory therapies. The company conducts clinical trials to test the safety and effectiveness of its products and works closely with regulatory agencies such as the US Food and Drug Administration (FDA) to obtain approval for its therapeutic products. Bellerophon Therapeutics markets its products directly to physicians and medical facilities, as well as through pharmaceutical companies and wholesalers. The company also utilizes digital marketing strategies such as social media campaigns to raise awareness of its products to a broader audience. Overall, Bellerophon Therapeutics is an innovative company focused on developing new therapies for severe respiratory diseases. The company has a well-developed pipeline of products and leverages successful research collaborations to advance its development activities. With the approval of INOpulse, Bellerophon Therapeutics has proven its ability to develop groundbreaking therapies and successfully bring them to the international market.

What is the Bellerophon Therapeutics dividend?

Bellerophon Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Bellerophon Therapeutics pay dividends?

The dividend cannot currently be calculated for Bellerophon Therapeutics or the company does not pay out a dividend.

What is the Bellerophon Therapeutics ISIN?

The ISIN of Bellerophon Therapeutics is US0787713009.

What is the Bellerophon Therapeutics WKN?

The WKN of Bellerophon Therapeutics is A2PZZR.

What is the Bellerophon Therapeutics ticker?

The ticker of Bellerophon Therapeutics is BLPH.

How much dividend does Bellerophon Therapeutics pay?

Over the past 12 months, Bellerophon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bellerophon Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bellerophon Therapeutics?

The current dividend yield of Bellerophon Therapeutics is .

When does Bellerophon Therapeutics pay dividends?

Bellerophon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bellerophon Therapeutics?

Bellerophon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bellerophon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bellerophon Therapeutics located?

Bellerophon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bellerophon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bellerophon Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Bellerophon Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Bellerophon Therapeutics in the year 2023?

In the year 2023, Bellerophon Therapeutics distributed 0 USD as dividends.

In which currency does Bellerophon Therapeutics pay out the dividend?

The dividends of Bellerophon Therapeutics are distributed in USD.

All fundamentals about Bellerophon Therapeutics

Our stock analysis for Bellerophon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bellerophon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.